Clinical Trial Applications - Stopped: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Stopped | |
|---|---|---|---|---|---|
31. |
ECCT/11/02/01 | Compare the Efficacy and Safety of Gentian Violet to that of Nystatin A5265 - A Phase III, Open-Label, Randomized, Assessment-Blinded Clinical Trial to Compare the Safety and Efficacy of Topical Gentian Violet to that of Nystatin Oral Suspension for the Treatment of Oropharyngeal Candidiasis in HIV-1 Infected Participants in Non-U.S. Settings |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) |
Not recorded |
View |
32. |
ECCT/23/02/04 | mRNA-1273-P203 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Dr Victor Mudhune Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. KEMRI/USAMRD (Kericho county) 3. Kenya Medical Research Institute/USAMRU (Kisumu county) 4. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 5. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 7. KEMRI/ CDC (Kisumu county) 8. KEMRI (Kisumu county) 9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) 10. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) |
Not recorded |
View |
33. |
ECCT/23/05/05 | mRNA-1273-P203 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Videlis Nduba Site(s) in Kenya 1. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 2. KEMRI/USAMRD (Kericho county) 3. Victoria Biomedical Research Institute (Kisumu county) 4. Kenya Medical Research Institute/USAMRU (Kisumu county) 5. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 6. KEMRI/ CDC (Kisumu county) 7. KEMRI (Kisumu county) 8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) 9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) |
Not recorded |
View |
34. |
ECCT/23/04/01 | mRNA-1273-P203 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Dr Janet Oyieko Site(s) in Kenya 1. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) 2. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 3. KEMRI/USAMRD (Kericho county) 4. Victoria Biomedical Research Institute (Kisumu county) 5. Kenya Medical Research Institute/USAMRU (Kisumu county) 6. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 7. KEMRI/ CDC (Kisumu county) 8. KEMRI (Kisumu county) 9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) |
Not recorded |
View |
35. |
ECCT/23/09/03 | CONSTELLATION A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Dr Simon Kariuki Site(s) in Kenya 1. Kenya Medical Research Institute- Centre for Global Health Research (Kisumu county) |
Not recorded |
View |
36. |
ECCT/19/12/02 | VPM1002 Phase III PoI A multicenter, Phase III double blind, randomized active controlled study to evaluate efficacy and safety of VPM1002 in comparison with BCG in prevention of Mycobacterium tuberculosis infection in newborn infants. |
Principal Investigator(s) 1. Videlis Nduba Site(s) in Kenya 1. KEMRI-CRDR Nairobi (Nairobi City county) 2. KEMRI-CRDR Siaya (Siaya county) |
Not recorded |
View |
37. |
ECCT/25/03/01 | MK-5684_MSD (mCRPC) A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) |
Principal Investigator(s) 1. PROF MANSOOR NOORALI SALEH Site(s) in Kenya AGA KHAN UNIVERSITY HOSPITAL NAIROBI |
Not recorded |
View |
38. |
ECCT/10/09/03 | A0661201 A0661201 AN OPEN LABEL, NON-COMPARATIVE STUDY TO EVALUATE PARASITOLOGICAL CLEARANCE RATES AND PHARMACOKINETICS OF AZITHROMYCIN AND CHLOROQUINE FOLLOWING ADMINISTRATION OF A FIXED DOSE COMBINATION OF AZITHROMYCIN AND CHLOROQUINE (AZCQ) IN ASYMPTOMATIC PREGNANT WOMEN WITH PLASMODIUMFALCIPARUM PARASITEMIA IN SUB-SAHARAN AFRICA |
Principal Investigator(s) 1. Joshua Kimani Site(s) in Kenya University of Nairobi Institute of Tropical and Infectious Diseases Siaya District Hospital |
Not recorded |
View |
39. |
ECCT/19/03/02 | PREVENT TD A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg daily or 550 mg twice daily) for Chemoprophylaxis Against Travellers’ Diarrhoea (TD) Among Active Duty Deployed U.S. and British Military Personnel (PREVENT TD) |
Principal Investigator(s) 1. Flynn Alexander Site(s) in Kenya Nyati Barracks, British Army Training Unit, Kenya |
Not recorded |
View |
40. |
ECCT/22/03/01 | The \"NOVATION-1\" Trial A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients with Moderate to Severe COVID-19 |
Principal Investigator(s) 1. Dr John Kinuthia Site(s) in Kenya 1. Center for Research in Therapeutic Sciences(CREATES) (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 3. KEMRI Kericho (Kericho county) 4. KEMRI Siaya (Kisumu county) 5. Kenyatta National Hospital (Nairobi City county) |
Not recorded |
View |